We rely on advice from our scientific advisors who assist us with internal triage of new applications and assessment of completed projects.
Professor Jim Owen
Professor Jim Owen is Emeritus Professor of Molecular Medicine at UCL. His research focused on lipoprotein metabolism, cell signalling and gene-based therapeutics, encompassing liver, cardiovascular and renal diseases, parasitic infections and Alzheimer’s disease.
Dr. Keith Bragman
Dr. Keith Bragman is a senior expert for the National Institute for Health and Care Excellence (NICE) and Immediate Past President of the Faculty of Pharmaceutical Medicine of The Royal Colleges of Physicians. He is a specialist in the development of novel medicines and clinical trial methodology particularly in the fields of haematology, oncology, infectious diseases, immunology and biotechnology.
Professor Andre McLean
Professor Andre McLean is an Emeritus Professor of Toxicology at UCL. His research focussed on the relationship between nutrition, toxicity and drug metabolism and he showed how methionine could be used to prevent the liver damage from paracetamol overdose. He has served on government advisory committees and the Committee on Safety of Medicines. At UCLH he was chair of the committee on Ethics of Human Research, and now continues to work as a consultant on safety of clinical trials.
Dr. Petra Disterer
Prior to joining Rosetrees, Dr. Petra Disterer was a senior post-doctoral scientist at UCL working on oligonucleotide therapeutics. In addition to working for Rosetrees, Petra works as a science writer for the Oligonucleotide Therapeutics Society.